Congratulations Bella on your graduation from @UWMadison as an @UW_AOS major and @ANTMET intern. May your future take you to the bottom of the planet and all the oceans in between!
Congratulations to @cgfran01, Pascal and the Apellis team! What an end to an incredible story that had every plot line in biotech and developed two important drugs for patients.
Apellis has agreed to be acquired by @Biogen — a testament to the impact of our medicines, the strength of our science, and the extraordinary talent of our team. Together, we expect to expand our reach and impact on patients. Read more: https://t.co/7tT0WvDDNc
We are pleased to announce a $5M investment into @zodl_app, alongside @a16z, @balajis, @winklevosscap, @cbventures, @friedberg, @paradigm & other leading investors
Our shareholders now have exposure to both private digital money & the most important privacy software company
👇
Cypherpunk Technologies is backing a world built on privacy and individual control. We’re proud to secure their treasury with Gemini’s institutional grade crypto custody.
The future is private and self-sovereign.
Today we launched Cypherpunk (@cypherpunktech), a company dedicated to privacy and self-sovereignty.
As the world becomes increasingly digitized, privacy has become a rare and precious commodity. Despite this, privacy enhancing technologies remain under-adopted. Backing privacy today is both a generational mission and a massive opportunity.
Privacy is the foundation that allows freedom of speech, thought, and association to thrive. Without it, these freedoms exist only on paper and can’t be exercised in practice in a meaningful way. In other words, privacy is the silent precondition of freedom.
In a world where privacy ceases to exist, it becomes the most valuable commodity.
This dynamic has captured our attention.
For the immediate future, we are directing our focus to Zcash ($ZEC). Zcash is the embodiment of privacy. It’s privacy in digital form.
We have already accumulated 203,775 ZEC at an average price of ~$245 per coin, representing ~1.25% of the current ZEC supply. We plan to continue accumulating ZEC rapidly so that Cypherpunk owns at least 5% of the total ZEC supply, while supporting development of Zcash and its ecosystem so privacy and self-sovereignty flourish.
Onward.
Privacy is the precondition for many of our freedoms. It’s the point at which government and corporate reach end and our individual freedoms and self-sovereignty begin. As our lives have moved online, privacy’s become a rare, vanishing commodity.
That’s why we founded Cypherpunk (@cypherpunktech) — a company dedicated to privacy and self-sovereignty. We will execute on our mission by accumulating, building, and supporting privacy-protecting assets and technologies at a time when the world needs them more than ever.
To that end, Cypherpunk — Ticker: $LPTX (today), $CYPH (tomorrow) — was launched with a $50 million+ investment from @winklevosscap to begin accumulating Zcash ($ZEC) at what we believe to be a significant discount to Zcash’s true long-term value. Cypherpunk currently holds 203,775 ZEC purchased at an average price of ~$245 per coin, representing ~1.25% of the current ZEC supply. We plan to continue accumulating ZEC rapidly so that Cypherpunk owns at least 5% of the total ZEC supply.
Since Zcash’s launch 9 years ago, we’ve observed its highly symbiotic relationship with bitcoin. Zcash is a fork of Bitcoin and shares identical tokenomics — both have a fixed total supply of 21 million coins. If bitcoin is digital gold, Zcash is encrypted bitcoin, or digital cash. One is your store of value, the other is how you privately move your value. We’ve been tracking this symbiosis for years and believe that now — as we enter the age of AI — is the right time to begin accumulating ZEC.
We feel strongly that Zcash could become a meaningful percentage of Bitcoin’s market capitalization — just on the merits of it being a privacy hedge or insurance policy to Bitcoin’s transparency alone. We believe bitcoin will continue to ascend to $1,000,000 per coin over the next 5-10 years. We also believe Zcash will appreciate significantly from here as well. These coins go hand in hand.
Over the next few weeks, we’ll continue to lay out our thesis. In the meantime, we’re excited to have you join us as we stack zats and invest in other technologies that promote privacy and self-sovereignty. Let us proceed together apace.
Onward.
Extremely proud of the @LeapTherapeutic team on the execution of this large randomized trial. Thank you to the patients, particularly in the control arm, families, physicians and staff. The insights are an important contribution to CRC research and the development of sirexatamab.
Catch the recording of Dr. Zev Weinberg’s presentation of the final DeFianCe data from #ESMO2025 showing that sirexatamab showed significantly improved PFS and OS in DKK1-High 2L CRC patients.
https://t.co/5O89XGJj9t
Leap has closed a $58.88M private placement led by @winklevosscap to kick off its digital asset treasury strategy and fuel continued progress of its lead clinical asset, sirexatamab, in patients with colorectal cancer.
https://t.co/YHY0AAVmOx
Excited to announce Leap has closed a $58.88 million financing led by @winklevosscap . Looking forward to working with them on the next steps for a new treatment for colorectal cancer patients and on a giant Leap into a bold new future. https://t.co/xRpt0nYjuA
Join @LeapTherapeutic ($LPTX) for a virtual KOL event on Wed, Apr. 23 at 2:30pm ET with Zev A. Wainberg, MD to discuss the unmet need and how sirexatamab (DKN-01) may improve upon current treatment landscape for patients with advanced MSS CRC. Register: https://t.co/RPyJpAhS7v
Amazing visit to the new home of #Vaxxas in #Brisbane. Inspiring to see the full team together to revolutionize the way that vaccines are delivered around the world.
First time back in #Brisbane since the pandemic. Terrific to visit our manufacturing partner for DKN-01 — @thermofisher . Thank you to the team here for six successful manufacturing campaigns. #Qld
Very appreciative of the strategic and institutional investors who are supporting us in our mission to bring new therapies to cancer patients around the world.
We’re excited to announce a $40 million equity financing. Thank you to our strategic and institutional investors for supporting our mission to develop DKN-01 to treat GI cancer patients around the world.
https://t.co/FxX2VCZSNE
Join us @JPMorgan’s 42nd Annual Healthcare Conference, 1/10/24, 1:30pm PT, to hear from our CEO Doug Onsi on Leap and our lead program, DKN-01. #JPM2024
https://t.co/pioFQZjqE3